CTIS2024-512580-31-00
Recruiting
Phase 1
ong-Term Follow-Up of Patients Who Have Received An Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR-Treg therapy, TX200-TR101) In A Prior Clinical study - TX200-KT03
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Kidney Transplant Rejection
- Sponsor
- Sangamo Therapeutics France
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects who enrolled in the Phase I/IIa study TX200\-KT02, received a transplanted kidney and have either completed or withdrawn from that study., 1\. Willing and able to provide written informed consent (IC) in accordance with local regulations and governing Independent Ethics Committee (IEC)/Institutional Review Board (IRB) requirements prior to any procedure or evaluation performed specifically for the sole purpose of the study.
Exclusion Criteria
- •1\. Subjects/ persons committed to an institution following an administrative or judicial order.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Allograft rejectionRenal transplant rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
Active, not recruiting
Phase 1
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2022-002440-40-DESangamo Therapeutics France SAS15
Active, not recruiting
Phase 1
ong term follow up for patients who have received NiCord/CordIn, stem cells from donated umbilical cord bloodthat were grown in a laboratory to expand their numberHigh risk haematological malignanciesHemoglobinopathiesMedDRA version: 18.1Level: LLTClassification code 10025316Term: Lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10040645Term: Sickle cell disease NOSSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2015-004813-26-ESGamida Cell Ltd76
Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.CTIS2024-511684-28-00Autolus Limited111
Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with an Autolus CAR T cell therapyEUCTR2016-004867-38-NLAutolus Limited500